All Stories

  1. Limitations of U25 CKiD and CKD-EPI eGFR formulae in patients 2–20 years of age with measured GFR > 60 mL/min/1.73 m2—a cross-sectional study
  2. Vertebral body reshaping after fractures: an important index of recovery in glucocorticoid-treated children
  3. Novel extracorporeal treatment for severe neonatal jaundice: A mathematical modelling study of allo-hemodialysis
  4. Limitations of U25 CKiD and CKD-EPI eGFR formulae in patients 2-20 years of age with measured GFR>60 mL/min/1.73 m2 – A cross-sectional study
  5. Plasma manganese and selenium levels in paediatric chronic kidney disease patients measured by high resolution sector field inductively coupled plasma mass spectrometry
  6. The urgent need for conducting clinical trials in pediatric nephrology globally
  7. The ongoing need to improve long‐term patient survival of pediatric solid organ recipients
  8. Artificial Intelligence in Pediatric Nephrology—A Call for Action
  9. Editorial: There Is Still a Need for Kidney Volume Reference Intervals in Large Children, Adolescents, and Young Adults
  10. Drug Use, Dosing, and Toxicity in Kidney Disease
  11. Sex differences of burosumab in children with X-linked hypophosphataemic rickets
  12. What to do with kidney length and volumes in large individuals?
  13. Ambulatory hypertension diagnosed by 24-h mean ambulatory versus day and night ambulatory blood pressure thresholds in children: a cross-sectional study
  14. Including Race in Pediatric Estimated GFR Equations: Is This a Genuine Need?
  15. Renal Autologous Cell Therapy to Stabilize Function in Diabetes-Related Chronic Kidney Disease: Corroboration of Mechanistic Action With Cell Marker Analysis
  16. GFR and eGFR in Term-born Neonates
  17. Biologic sex and the estimation of GFR in pediatric and young adult patients with acute kidney injury
  18. Impaired kidney function >90 days determines long‐term kidney outcomes
  19. Functional Sodium MRI Helps to Measure Corticomedullary Sodium Content in Normal and Diseased Human Kidneys
  20. Renal volume of five-year-old preterm children are not different than full-term controls
  21. Young Adults With Hereditary Tubular Diseases: Practical Aspects for Adult-Focused Colleagues
  22. Is there a case for early treatment with IVIG for BK transplant nephropathy?
  23. Outcomes and predictors of skin sodium concentration in dialysis patients
  24. Still trouble with serum creatinine measurements
  25. Histopathological Changes of Long-Term Peritoneal Dialysis Using Physiological Solutions: A Case Report and Review of the Literature
  26. Kt/V or Bicarbonate: What Is More Important for Growth in Pediatric Peritoneal Dialysis Patients?
  27. Assessment of Kidney Function in Children, Adolescents, and Young Adults
  28. Drug Dosing in Abnormal Kidney Function in Children
  29. Health Care Transition From Pediatric- to Adult-Focused Care in X-linked Hypophosphatemia: Expert Consensus
  30. Postoperative outcomes of ureteroscopy for pediatric urolithiasis: A secondary analysis of the National Surgical Quality Improvement Program Pediatric
  31. Animal, Human, and 23Na MRI Imaging Evidence for the Negative Impact of High Dietary Salt in Children
  32. Discrepant changes of urinary cystatin C and other urinary biomarkers in preterm neonates
  33. Management of severe polyuria in idiopathic Fanconi syndrome
  34. Transition from paediatric to adult-focused care: unresolved issues
  35. Marginal parent donors—Process and ethics
  36. Abdominal compartment syndrome secondary to chronic constipation in MECP2 duplication syndrome
  37. Low agreement between kidney volume and kidney length z-scores
  38. An Interdisciplinary Approach to Optimize the Care of Transitioning Adolescents and Young Adults with CKD
  39. Assessment of Kidney Function in Children, Adolescents, and Young Adults
  40. Drug Dosing in Abnormal Kidney Function in Children
  41. Automated Office Blood Pressure Measurement for the Diagnosis of Hypertension
  42. Adolescent and Caregiver Attitudes Towards Telemedicine Use in Pediatric Nephrology
  43. How should we assess renal function in neonates and infants?
  44. Renal length z‐score for the detection of dysfunction in children with solitary functioning kidney
  45. Transient hyponatremia of prematurity caused by mild Bartter syndrome type II: a case report
  46. Lower prevalence of aortic dilatation among preemptive pediatric renal transplant recipients – A cross‐sectional cohort study
  47. Comparative Analysis of American Heart Association and European Society of Hypertension Ambulatory Blood Pressure Thresholds for Diagnosing Hypertension in Children
  48. Late referrals of pediatric patients with elevated blood pressure
  49. Estimation of GFR in Patients With Cystic Fibrosis: A Cross-Sectional Study
  50. High depression rates among pediatric renal replacement therapy patients: A cross‐sectional study
  51. Chromium: Rise and Shine in Peritoneal Dialysis Patients?
  52. Kidney disease and organ transplantation in methylmalonic acidaemia
  53. Educational review: role of the pediatric nephrologists in the work-up and management of kidney stones
  54. Appreciating the need for greater understanding of the pharmacokinetics of drugs in children and adolescents
  55. A Cross-Sectional Study of Growth and Metabolic Bone Disease in a Pediatric Global Cohort Undergoing Chronic Hemodialysis
  56. Nephrological and urological complications of homozygous c.974G>A (p.Arg325Gln) OSGEP mutations
  57. Low agreement between modified-Schwartz and CKD-EPI eGFR in young adults: a retrospective longitudinal cohort study
  58. The urgent need for more research on how to treat recurrent focal and segmental glomerulosclerosis
  59. Does specialist physician supply affect pediatric asthma health outcomes?
  60. Successful Reintroduction of Peritoneal Dialysis after Peritoneal-Pericardial Fistula in a Child: A Case Report
  61. The importance of cardiovascular disease in pediatric transplantation and its link to the kidneys
  62. Is there a case for eculizumab for pediatric renal transplantation?
  63. We have to do more for former paediatric renal transplant recipients!
  64. Methodology of Casual Blood Pressure Measurement
  65. Educational review: measurement of GFR in special populations
  66. Innovating to educate paediatric consultant generalists for the new Canadian health care
  67. Chronic kidney disease stage affects small, dense low-density lipoprotein but not glycated low-density lipoprotein in younger chronic kidney disease patients: a cross-sectional study
  68. Is it time for a multi-specialty approach to cardio-renal dysfunction in children with cyanotic congenital heart disease?
  69. A case control analysis investigating risk factors and outcomes for nephrocalcinosis and renal calculi in neonates
  70. High prevalence of elevated molybdenum levels in pediatric CKD patients. A cross-sectional and longitudinal study
  71. Generic immunosuppressants
  72. Deviations from the expected relationship between serum FGF23 and other markers in children with CKD: a cross-sectional study
  73. A Retrospective Study on Mycophenolic Acid Drug Interactions: Effect of Prednisone, Sirolimus, and Tacrolimus With MPA
  74. Improving the translation of novel biomarkers to clinical practice: The story of cystatin C implementation in Canada
  75. A cross-sectional study measuring vanadium and chromium levels in paediatric patients with CKD
  76. Improving long-term outcomes after pediatric renal transplantation by addressing dyslipidemia
  77. Barriers to the Implementation of Lipoprotein Apheresis in Canada
  78. Spot urine protein to creatinine ratio
  79. Idiosyncratic drug reactions and membranous glomerulopathy
  80. Successful treatment of multiple angiomyolipomas with sirolimus in a child
  81. Methodology of Casual Blood Pressure Measurement
  82. Is Fibroblast Growth Factor 23 the New Biomarker for Cardiovascular Mortality in Chronic Kidney Disease Patients?
  83. Is a reduction in cystometric bladder capacity in anuric infants post-renal transplant really no big deal?
  84. Is Testosterone Detrimental to Renal Function?
  85. Three novel mutations in patients with hypomagnesemia
  86. Can the new CKD-EPI BTP-B2M formula be applied in children?
  87. Are Tacrolimus Pharmacokinetics Affected by Nephrotic Stage?
  88. Chronic kidney disease and cardiac morbidity — What are the possible links?
  89. How to estimate glomerular filtration rate (GFR) in pediatric cardiac patients
  90. Online Calculator to Improve Counseling of Short-Term Neonatal Morbidity and Mortality Outcomes at Extremely Low Gestational Age (23–28 Weeks)
  91. Practice recommendations: A new type of article inPediatric Transplantation
  92. Assessment of glomerular filtration rate in the neonate
  93. The compelling case for therapeutic drug monitoring of mycophenolate mofetil therapy
  94. Practice recommendations for the monitoring of renal function in pediatric non-renal organ transplant recipients
  95. Developmental changes of MPA exposure in children
  96. The Search for More Reliable Estimated GFR Biomarkers
  97. Minimum mycophenolic acid levels are associated with donor-specific antibody formation
  98. Handling of Drugs in Children with Abnormal Renal Function
  99. What is the intrapatient variability of mycophenolic acid trough levels?
  100. The 99mTc-DTPA Urinary Clearance Method May Be Preferable to the Plasma Disappearance Method for Assessing Glomerular Filtration Rate in Diabetic Nephropathy
  101. The Importance of Accurately Assessing Renal Function in the Neonate and Infant
  102. The Kinetics of Cystatin C Removal by Hemodialysis
  103. The merits of sequential transplantation for hyperoxaluria type I
  104. Estimation of GFR Using  -Trace Protein in Children
  105. The Health Initiative Program for Kids (HIP Kids): effects of a 1-year multidisciplinary lifestyle intervention on adiposity and quality of life in obese children and adolescents - a longitudinal pilot intervention study
  106. The Need for Tacrolimus Assay Standardization
  107. Finding the optimal therapeutic window for tacrolimus
  108. A Single-Gene Cause in 29.5% of Cases of Steroid-Resistant Nephrotic Syndrome
  109. Euvolemia in Hemodialysis Patients: A Potentially Dangerous Goal?
  110. Beta-trace protein as a marker of GFR — History, indications, and future research
  111. Only some generic immunosuppressants are safe.
  112. Rapid Resolution of Tacrolimus Intoxication–Induced AKI With a Corticosteroid and Phenytoin
  113. Comparison of clinical and biochemical markers of dehydration with the clinical dehydration scale in children: a case comparison trial
  114. Similar MPA Exposure on Modified Release and Regular Tacrolimus
  115. Combined liver-kidney transplantation for hyperoxaluria type II?
  116. β-trace protein may be a more suitable marker of neonatal renal function
  117. Do we need to worry about mycophenolate overdose?
  118. Using individual DSA titers to assess for accommodation after late humoral rejection
  119. No Association Between Cyclosporine Levels and Dyslipidemia?
  120. Cyproheptadine for central hypertension?
  121. ACE levels may affect cystatin C measurements
  122. Measuring Physicians’ Productivity
  123. The Canadian Childhood Nephrotic Syndrome (CHILDNEPH) Project: Overview of Design and Methods
  124. What Is Single Needle Cannulation Hemodialysis: Is It Adequate?
  125. Are the children and adolescents with congenital heart disease living in Southwestern Ontario really overweight and obese?
  126. Tandem hemodialysis and plasma exchange
  127. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome
  128. Trace elements in dialysis
  129. Rising Part-Time Work in the Academic Pediatric Workforce in Canada
  130. Nighttime blood pressure, systolic blood pressure variability, and left ventricular mass index in children with hypertension
  131. Evaluating Canadian children: WHO, NHANES or what?
  132. Native kidney BK virus nephropathy associated with acute lymphocytic leukemia
  133. Cystatin C adaptation in the first month of life
  134. Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study
  135. Methods of assessing renal function
  136. The need for ongoing monitoring of adherence to access targets
  137. High prevalence of renal dysfunction also after small bowel transplantation
  138. Non-invasive measurement of cardiac output in obese children and adolescents: comparison of electrical cardiometry and transthoracic Doppler echocardiography
  139. Are Canadian pediatric nephrology patients really overweight?
  140. Antibody Mediated Rejection Associated With Complement Factor H–Related Protein 3/1 Deficiency Successfully Treated With Eculizumab
  141. Why multidisciplinary clinics should be the standard for treating chronic kidney disease
  142. Cystatin C for the assessment of GFR in neonates with congenital renal anomalies
  143. High prevalence of elevated lead levels in pediatric dialysis patients
  144. High prevalence of hypertension and renal glomerular and tubular dysfunction after orthotopic liver transplantation*
  145. Are fibroblast growth factor 23 concentrations in renal transplant patients different from non-transplanted chronic kidney disease patients?
  146. Should we consider MMF therapy after rituximab for nephrotic syndrome?
  147. Monitoring and improving renal outcomes after heart transplantation
  148. Preliminary reference intervals for cystatin C and beta-trace protein in preterm and term neonates
  149. The effect of seniority and education on departmental dictation utilization
  150. Diagnostic Accuracy of Cystatin C–Based eGFR Equations at Different GFR Levels in Children
  151. The Authors Reply:
  152. Skeletal findings in children recently initiating glucocorticoids for the treatment of nephrotic syndrome
  153. Impaired GFR is the most important determinant for FGF-23 increase in chronic kidney disease
  154. Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation
  155. Cystatin C Reduction Ratio Depends on Normalized Blood Liters Processed and Fluid Removal during Hemodialysis
  156. Hyperfiltration Affects Accuracy of Creatinine eGFR Measurement
  157. Prevention of chronic kidney disease in spina bifida
  158. Challenges in pediatric transplantation: The impact of chronic kidney disease and cardiovascular risk factors on long‐term outcomes and recommended management strategies
  159. Are we ready to use aliskiren in children?
  160. Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets
  161. Association Between Clinical Risk Factors and Progression of Chronic Kidney Disease in Children
  162. Residual renal function assessment with cystatin C
  163. Variability of the Pediatric Subspecialty Workforce in Canada
  164. Big Mother or Small Baby: Which Predicts Hypertension?
  165. Cystatin C Measurements in the Assessment of Residual Renal Function, Dialysis Adequacy, and Beyond
  166. Progress in Pediatric Kidney Transplantation
  167. Racial Disparities in Hemoglobin Concentration in Children With CKD
  168. Pediatric reference intervals for immunoglobulin G and its subclasses with Siemens immunonephelometric assays
  169. Prevalent vertebral fractures among children initiating glucocorticoid therapy for the treatment of rheumatic disorders
  170. Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease
  171. Epidemiology of pediatric urolithiasis
  172. Rituximab in refractory nephrotic syndrome
  173. Limited sampling strategies for sirolimus after pediatric renal transplantation
  174. Effect of Clinical Variables and Immunosuppression on Serum Cystatin C and Beta-Trace Protein in Kidney Transplant Recipients
  175. Cystatin C Levels in Functionally Anephric Patients Undergoing Dialysis
  176. Estimating GFR using serum beta trace protein: accuracy and validation in kidney transplant and pediatric populations
  177. Picture of the Month—Quiz Case
  178. Bicarbonate therapy improves growth in children with incomplete distal renal tubular acidosis
  179. Advanced Vertebral Fracture Among Newly Diagnosed Children With Acute Lymphoblastic Leukemia: Results of the Canadian Steroid‐Associated Osteoporosis in the Pediatric Population (STOPP) Research Program
  180. Pediatric reference intervals for soluble transferrin receptor and transferrin receptor-ferritin index
  181. Monitoring kidney function and renal disease in children following transplant
  182. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab
  183. Characterization of sirolimus metabolites in pediatric solid organ transplant recipients
  184. High prevalence of chronic kidney disease in pediatric solid organ transplantation
  185. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy
  186. Anemia and Risk of Hospitalization in Pediatric Chronic Kidney Disease
  187. Relationships Among Serum Iron, Inflammation, and Body Mass Index in Children
  188. Shorter break‐in period is a viable option with tighter PD catheter securing during the insertion
  189. Body mass does not have a clinically relevant effect on cystatin C eGFR in children
  190. Cardiac tamponade in diarrhoea-positive haemolytic uraemic syndrome
  191. Myfortic in pediatric transplantation
  192. Remission of steroid-resistant nephrotic syndrome due to focal and segmental glomerulosclerosis using rituximab
  193. Pharmacokinetics of Mycophenolate Mofetil and Sirolimus in Children
  194. Albuminuria and Estimated GFR 5 Years After Escherichia coli O157 Hemolytic Uremic Syndrome: An Update
  195. Should prevention of chronic kidney disease start before pregnancy?
  196. Complications of chronic kidney disease in children post‐renal transplantation – A single center experience
  197. Extracorporeal Therapies for Poisoning
  198. How to monitor renal function in pediatric solid organ transplant recipients
  199. A Novel Equation to Estimate Glomerular Filtration Rate Using Beta-Trace Protein
  200. Novel HGPRT 293 A>G point mutation presenting as neonatal acute renal failure
  201. Chronic kidney disease stage in renal transplantation classification using cystatin C and creatinine-based equations
  202. Incomplete distal renal tubular acidosis affects growth in children
  203. Safety considerations with mycophenolate sodium
  204. How to define anemia in children with chronic kidney disease?
  205. Optimization of Immunosuppressive Drug Monitoring in Children
  206. Unexpectedly high inter‐ and intrapatient variability of Ganciclovir levels in children
  207. Calcineurin Inhibitors in Pediatric Renal Transplant Recipients
  208. Is it premature to use calcineurin-inhibitor-free immunosuppression in pediatric renal transplantation?
  209. Reference Intervals for Anion Gap and Strong Ion Difference in Pregnancy: A Pilot Study
  210. Growth impairment shows an age-dependent pattern in boys with chronic kidney disease
  211. Pharmacokinetics of Pyridostigmine in a Child With Postural Tachycardia Syndrome
  212. How to Measure Renal Function in Children - What is the Role of Cystatin C?
  213. Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing
  214. Association between air pollution and general practitioner visits for respiratory diseases in Hong Kong
  215. How to assess for impaired glucose tolerance before transplantation and should these results influence the choice of calcineurin inhibitors?
  216. Cystatin C Intrapatient Variability in Children with Chronic Kidney Disease Is Less than Serum Creatinine
  217. Influence of commonly used drugs on the accuracy of cystatin C-derived glomerular filtration rate
  218. Tissue viral DNA is associated with chronic allograft nephropathy
  219. Adding Sirolimus to Tacrolimus‐Based Immunosuppression in Pediatric Renal Transplant Recipients Reduces Tacrolimus Exposure
  220. Four‐year data after pediatric renal transplantation: A randomized trial of tacrolimus vs. cyclosporin microemulsion
  221. Neonatal Renal Venous Thrombosis: Clinical Outcomes and Prevalence of Prothrombotic Disorders
  222. The Cockcroft-Gault formula should not be used in children
  223. Pseudomonas aeruginosa infection: An uncommon cause of post‐renal obstruction following induction therapy for acute lymphoblastic leukemia
  224. Changing trends in the referral patterns of pediatric nephrology patients
  225. Icodextrin re-absorption varies with age in children on automated peritoneal dialysis
  226. Cystatin‐C and beta trace protein as markers of renal function in pregnancy
  227. Plasma Exchange Using a Continuous Venovenous Hemofiltration Machine in Children
  228. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady‐state pharmacokinetics of tacrolimus in renal transplant patients
  229. To what extent does the understanding of pharmacokinetics of mycophenolate mofetil influence its prescription
  230. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation
  231. The safety and use of short-acting nifedipine in hospitalized hypertensive children
  232. Drug interactions between mycophenolate and cyclosporine
  233. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna
  234. Errata
  235. Patients with autosomal dominant polycystic kidney disease hyperfiltrate early in their disease
  236. Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy
  237. Is there really an increase in non-minimal change nephrotic syndrome in children?
  238. One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience1
  239. Tissue HHV6 and 7 determination in pediatric solid organ recipients − a pilot study
  240. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome
  241. Is decreased bone mineral density in pediatric transplant recipients really a problem?
  242. Should the Schwartz formula for estimation of GFR be replaced by cystatin C formula?
  243. Evidence-based immunosuppression after pediatric renal transplantation—A dream?
  244. Measuring Glomerular Filtration Rate with Cystatin C and β-Trace Protein in Children with Spina Bifida
  245. Another case of HBV associated membranous glomerulonephritis resolving on lamivudine
  246. Glomerular filtration rate as a putative ‘surrogate end‐point’ for renal transplant clinical trials in children
  247. Quantitative tissue polymerase chain reaction for Epstein-Barr virus in pediatric solid organ recipients
  248. Confirmation of the ATP6B1 gene as responsible for distal renal tubular acidosis
  249. Cystatin C should be measured in pediatric renal transplant patients!
  250. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children
  251. Combination of ceftriaxone and acyclovir – an underestimated nephrotoxic potential?
  252. One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion
  253. Cyclosporin A monitoring and AUC determination – where do we go?
  254. Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy
  255. G protein β3 subunit 825T genotype is not associated with differing outcome in pediatric renal transplant recipients
  256. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation
  257. The emerging role of gene polymorphisms determining outcome after solid‐organ transplantation
  258. Effect of Cyclosporine on Mycophenolic Acid Area Under the Concentration–Time Curve in Pediatric Kidney Transplant Recipients
  259. Antibody Response to Shiga Toxins Stx2 and Stx1 in Children with Enteropathic Hemolytic-Uremic Syndrome
  260. Renin angiotensin system gene polymorphisms in pediatric renal transplant recipients
  261. Analysis of Cognitive and Motor Functioning during Pubertal Development: A New Approach.
  262. Macrohematuria with electron-dense deposits in a 14-year-old boy with minimal change nephrotic syndrome
  263. Glucose metabolism in children with renal failure: oral or intravenous glucose tolerance
  264. Does growth hormone therapy harmonize distorted morphology and body composition in chronic renal failure?
  265. Bioimpedance and inferior vena cava diameter for assessment of dialysis dry weight
  266. Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity
  267. Functional Characterization of the Molecular Defects Causing Nephrogenic Diabetes Insipidus in Eight Families
  268. Limited Sampling Strategy for Mycophenolic Acid Area Under the Curve
  269. Evaluation of pediatric nephropathies by a computerized Urine Protein Expert System (UPES)
  270. Long-term prognosis of hemolytic uremic syndrome and effective renal plasma flow
  271. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate
  272. Non-random distribution of mutations in the PHEX gene, and under-detected missense mutations at non-conserved residues
  273. Abbreviated cyclosporine AUCs on Neoral - the search continues!
  274. Slowly deteriorating insulin secretion and C-peptide production characterizes diabetes mellitus in infantile cystinosis
  275. Glucose Tolerance and Insulin Secretion in Children before and during Recombinant Growth Hormone Treatment
  276. Reversible diabetes mellitus during growth hormone therapy in chronic renal failure
  277. Nierenersatztherapie von osteuropäischen Kindern und Jugendlichen in Westeuropa
  278. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants
  279. A child with haemolytic uraemic syndrome: do we have to care about aetiological heterogeneity?
  280. Mycophenolate mofetil for rescue therapy in acute renal transplant rejection in children should always be monitored by measurement of trough concentration
  281. Transient diabetes mellitus and peripheral insulin resistance following Tacrolimus intoxication in a child after renal transplantation
  282. Which cyclosporin formulation?
  283. Growth Hormone as a New Treatment Modality for Short Children with Chronic Renal Failure
  284. Neutrophil activation in the haemolytic uraemic syndrome: free and complexed elastase in plasma